Company / R&D Expense
Processa Pharmaceuticals, Inc. R&D Expense History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$6.9M
FY2022
5-year range
$29.2K / $6.9M
FY2018-FY2022
Trend
+116.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $29,246 to $7M over the past 6 years.
Based on SEC 10-K filings.
$7M in FY2022.
Improved from $29,246 to $7M over the past 6 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, r&d expense increased 116.8% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $6.9M | +116.8% |
| FY2021 | $3.2M | +10747.2% |
| FY2016 | $29.2K | -83.6% |
| FY2015 | $178.1K | -33.3% |
| FY2014 | $267.1K | -40.4% |
| FY2013 | $448.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026